research Endocrinological evaluation and hormonal therapy for women with difficult acne
Hormonal therapy is a good option for women with severe acne, especially when there's a chance of hormone imbalance.
Search
for
Sort by
Research
840-870 / 1000+ results research The Opiate Antagonist, Naltrexone, in the Treatment of Trichotillomania
Naltrexone did not significantly reduce hair pulling but improved cognitive flexibility.
research Topical lotion beneficial in androgenetic alopecia
Lotion with piroctone olamine and triclosan improves hair loss in men.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Clinical assessment of CL22209, a standardized proprietary extract of Asparagus racemosus, for mitigating vasomotor and menstrual symptoms in perimenopausal women: A randomized, double-blind, placebo-controlled study
CL22209, an Asparagus racemosus extract, safely reduces perimenopausal symptoms and balances hormones.
research Cyclosporine
Nonimmunosuppressive cyclosporines might treat skin diseases by affecting cell growth.
research Co-Drug Strategy for Promoting Skin Targeting and Minimizing the Transdermal Diffusion of Hydroquinone and Tranexamic Acid
HAC and BAC improve skin targeting and reduce diffusion without causing irritation.
research 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
research Evaluation of the efficacy of topical metformin 10% and 20% versus topical potent steroid in the treatment of patients with alopecia areata
Topical metformin gel is as effective and safe as steroids for treating alopecia areata.
research Oral Tofacitinib for Refractory Lichen Planus Pigmentosus Coexisting with Frontal Fibrosing Alopecia
Tofacitinib significantly improved skin and hair conditions without side effects.
research Alefacept for Severe Alopecia Areata
Alefacept does not effectively treat severe alopecia areata.
research Hair Casts
Tretinoin lotion can remove hair casts, which come from a specific part of the hair follicle and can be classified into two types.
research A single topical application of calcipotriol (50μg/g) ointment has no acute effect on systemic calcium homeostasis in patients with chronic plaque psoriasis
Putting calcipotriol ointment on the skin once doesn't change calcium levels in the body right away.
research Identification of drug-specific public TCR driving severe cutaneous adverse reactions
Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
research Compatibility of Cetirizine Hydrochloride, Dutasteride, Hydrocortisone Acetate, Nicotinamide, Progesterone, and Pyridoxine Hydrochloride in TrichoSolTM, A Natural Vehicle for Hair Solutions.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
research A Case of Cronkhite-Canada Syndrome with Telogen Effluvium and Onycholysis
Prednisolone treatment improved symptoms and hair regrowth in a patient with Cronkhite-Canada Syndrome.
research Comparative study between intralesional injection of prostaglandin F2α alone or combined with corticosteroids in the treatment of alopecia areata
Combining TRA and latanoprost is most effective for treating localized alopecia areata.
research [Acitretine].
Acitretin treats severe skin conditions but requires careful monitoring due to serious side effects.
research Candida antigen immunotherapy versus steroid in the treatment of alopecia areata
Candida antigen is an effective and promising treatment for alopecia areata.
research PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS
CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
research Bilateral non-specific orbital inflammation (orbital "pseudotumour"), posterior scleritis, and anterior uveitis associated with hypothyroidism in a child
Intralesional cidofovir might be a viable alternative treatment for certain conditions.
research New Antifungal Agents and New Formulations Against Dermatophytes
New topical antifungals and delivery systems are improving treatment for fungal skin infections, but patient education and prevention are key.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Novel potential avenues for the therapy of Tourette syndrome: Cannabinoid- and steroid-based interventions
Cannabinoid and steroid-based drugs could be new treatments for Tourette syndrome, but more research is needed to confirm their effectiveness and safety.
research Prognostic factors that affect the response to topical treatment in patchy alopecia areata
Certain factors like allergies, nail problems, and hair loss patterns can predict how well someone with patchy hair loss will respond to skin cream treatments.
research Compound Platycladus orientalis Tincture Promotes Hair Regrowth and Is Associated with Hair-Cycle Progression and Wnt/β-Catenin-Related Signaling
research 42146 Concurrent improvement in scalp hair and eyebrow or eyelash regrowth in patients with severe alopecia areata treated with baricitinib
Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
research Tamoxifen-Induced Total Alopecia
Tamoxifen can cause total hair loss but its benefits outweigh this side effect.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.